| 1. |
- van Bragt, JJMH, et al.
(författare)
-
Characteristics and treatment regimens across ERS SHARP severe asthma registries
- 2020
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 55:1
-
Tidskriftsartikel (refereegranskat)abstract
- Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Christensen, Torben, et al.
(författare)
-
Factors controlling large scale variations in methane emissions from wetlands
- 2003
-
Ingår i: Geophysical Research Letters. - 0094-8276 .- 1944-8007. ; 30:7
-
Tidskriftsartikel (refereegranskat)abstract
- [1] Global wetlands are, at estimate ranging 115-237 Tg CH4/yr, the largest single atmospheric source of the greenhouse gas methane (CH4). We present a dataset on CH4 flux rates totaling 12 measurement years at sites from Greenland, Iceland, Scandinavia and Siberia. We find that temperature and microbial substrate availability (expressed as the organic acid concentration in peat water) combined explain almost 100% of the variations in mean annual CH4 emissions. The temperature sensitivity of the CH4 emissions shown suggests a feedback mechanism on climate change that could validate incorporation in further developments of global circulation models.
|
|
| 5. |
- Haapanala, S., et al.
(författare)
-
Mountain birch - potentially large source of sesquiterpenes into high latitude atmosphere
- 2009
-
Ingår i: Biogeosciences. - 1726-4189. ; 6:11, s. 2709-2718
-
Tidskriftsartikel (refereegranskat)abstract
- Emissions of volatile organic compounds (VOCs) from mountain birches were measured in Abisko, northern Sweden. Mountain birches make up the majority of the tree biomass in Scandinavian high latitudes, a region subject to significant climate warming. The measurements were carried out in two growing seasons. The emissions of four branches, each from a different individual tree, were measured in June-August 2006 and one of them again in July 2007. The measurements were conducted using a dynamic flow through chamber covered with Teflon film. The studied mountain birches were found to emit substantial amounts of linalool, monoterpenes and sesquiterpenes. The monoterpene emission was dominated by sabinene. The magnitude and composition of the sesquiterpene emission changed dramatically between the years. For example, the average alpha-farnesene emission potential in 2006 was almost 2600 ng g(dw)(-1) h(-1) (3.5 pmol g(dw)(-1) s(-1)) while in 2007 alpha-farnesene was not detected at all. Also the emissions of other sesquiterpenes decreased in 2007 to a fraction of that in 2006. One possible explanation for the change in emissions is the herbivory damage that occurred in the area in 2004. Herbivory is known to enhance the emissions of sesquiterpenes, especially those of alpha-farnesene, and the effect may last for several years.
|
|
| 6. |
- Main, Chris J., et al.
(författare)
-
Implementation Science and Employer Disability Practices : Embedding Implementation Factors in Research Designs
- 2016
-
Ingår i: Journal of occupational rehabilitation. - : Springer-Verlag New York. - 1053-0487 .- 1573-3688. ; 26:4, s. 448-464
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: For work disability research to have an impact on employer policies and practices it is important for such research to acknowledge and incorporate relevant aspects of the workplace. The goal of this article is to summarize recent theoretical and methodological advances in the field of Implementation Science, relate these to research of employer disability management practices, and recommend future research priorities.Methods: The authors participated in a year-long collaboration culminating in an invited 3-day conference, “Improving Research of Employer Practices to Prevent Disability”, held October 14–16, 2015, in Hopkinton, MA, USA. The collaboration included a topical review of the literature, group conference calls to identify key areas and challenges, drafting of initial documents, review of industry publications, and a conference presentation that included feedback from peer researchers and a question/answer session with a special panel of knowledge experts with direct employer experience.Results: A 4-phase implementation model including both outer and inner contexts was adopted as the most appropriate conceptual framework, and aligned well with the set of process evaluation factors described in both the work disability prevention literature and the grey literature. Innovative interventions involving disability risk screening and psychologically-based interventions have been slow to gain traction among employers and insurers. Research recommendations to address this are : (1) to assess organizational culture and readiness for change in addition to individual factors; (2) to conduct process evaluations alongside controlled trials; (3) to analyze decision-making factors among stakeholders; and (4) to solicit input from employers and insurers during early phases of study design.Conclusions: Future research interventions involving workplace support and involvement to prevent disability may be more feasible for implementation if organizational decision-making factors are imbedded in research designs and interventions are developed to take account of these influences.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Young, M. H. H., et al.
(författare)
-
Immunosuppression and treatment of rejection in uterus transplantation: Current practice and future potential
- 2019
-
Ingår i: Uterus Transplantation. Brännström, M. (red.). - Cham : Springer. - 9783319941622 ; , s. 151-166
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Uterus transplantation has recently been introduced as a novel infertility treatment in a small number of centers around the world. In this chapter, the immunosuppressive armamentarium at our current disposal will be discussed. We will also examine recent immunosuppression protocols employed as induction, maintenance, and rejection treatment for uterus transplantation and discuss specific aspects of immunosuppression during pregnancy. Moreover, future aspects of immunosuppression in uterus transplantation will be discussed. © Springer Nature Switzerland AG 2020.
|
|
| 10. |
- Östraat, Ö., et al.
(författare)
-
Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro
- 1996
-
Ingår i: Transplant Immunology. - 1878-5492. ; 4:2, s. 117-125
-
Tidskriftsartikel (refereegranskat)abstract
- The effects of thalidomide on in vitro interleukin 2 (IL-2) production and thymidine uptake by human peripheral blood lymphocytes or rat splenocytes were investigated. Phytohaemagglutinin-stimulated human lymphocytes were incubated in the presence of thalidomide added at culture initiation. No immunosuppressive effect of thalidomide was observed in these experiments. Primary human mixed lymphocyte cultures treated with thalidomide for 6 days were also unaffected. A microsomal rabbit liver homogenate was prepared for metabolizing thalidomide. Stimulated lymphocytes secreted significantly more IL-2 in the presence of microsomal-treated thalidomide than did controls. The effect of thalidomide was then studied either as single therapy or in combination with cyclosporin A (CyA) in a rat allograft cardiac transplantation model. In addition, T cell subsets were analysed by flow cytometry in untransplanted rats treated with thalidomide. Treatment was given as induction therapy from the day of transplantation until day 9. Graft survival in rats treated with thalidomide was significantly prolonged compared to the untreated group. No difference in graft survival was detected between rats treated with thalidomide or CyA only. Graft survival was found to be slightly prolonged in rats given thalidomide and CyA in combination compared to rats treated with CyA alone. In untransplanted rats given thalidomide a decrease of CD4 positive T cells was detected on days 3 and 5. The T helper/cytotoxic-suppressor cell ratio was significantly diminished but, after 1 week of treatment, values for T cell subsets had almost returned to baseline levels. No inhibitory effect was obtained when phytohaemagglutinin-stimulated rat splenocytes were cultured with metabolized thalidomide.In summary, the ability of thalidomide to improve allograft survival in a solid organ transplant model was verified. The occurrence of thalidomide-induced changes in T cell subset ratios was demonstrated. In in vitro studies, however, there was no decrease but an increase in IL-2 production, and no change in thymidine uptake. The mechanism responsible for the immunosuppressive effect of thalidomide remains to be elucidated.
|
|
